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ABSTRACT  
VIRUS-LIKE PARTICLES GENERAGED BY EXPRESSING PROTEINS OF 
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) 
USING THE RECOMBINANT BACULOVIRUS EXPRESSION SYSTEM  
APRIL ANNE NELSEN 
2015 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped, 
single stranded, positive sense RNA virus and a member of Arteriviridae.  Its genome 
encodes 10 open reading frames for at least 7 structural proteins and 14 non-structural 
proteins.  Membrane (M), Nuclepcapsid (N), and Glycoprotein-5 (GP5) are the major 
structural proteins of PRRSV, while Envelope (E), Glycoprotein-2 (GP2), Glycoprotein-3 
(GP3), and Glycoprotein-4 (GP4) are the minor structural proteins of PRRSV.  GP5 
induces neutralizing antibodies and forms heterodimers with M, while N is the most 
immunogenic protein of PRRSV.  Previous studies have shown viral structural proteins 
are able to form virus-like particles (VLPs) that can induce an immune response in 
respective hosts by use of the recombinant baculovirus expression system in insect cells. 
We sought to find if structural proteins, M, N, GP5, GP4, and E, could be expressed 
using the recombinant baculovirus expression system and produce VLPs. 
After purifying and amplifying PRRSV GP4, GP5, and E genes from PRRSV 
viral RNA, we inserted those genes into the pCAGEN plasmid, and expressed them in 
mammalian cells (cos-1). Protein expression of E and GP5 in both the supernatant and 
cell lysate was verified through western blot, while GP4 was not.  We inserted the 
expressed genes into the pOET-1 plasmid for production of recombinant baculoviruses 
 x 
using the flashBAC expression system in insect cells. Expression of GP5 and E proteins 
were verified with IFA.  Viral titers were collected using bacuQUANT qRT-PCR, and 
used to co-infect TriEx SF9 cells with recombinant baculoviruses containing PRRSV M, 
N, GP5, and E at a multiplicity of infection (MOI) of 2 for N, GP5, and E proteins and a 
MOI of 3 for M protein for 72 hours.  Protein expression was confirmed through western 
blot. The results of this experiment show that PRRSV M, N, GP5, and E proteins are 
expressed after co-infection of TriEx SF9 cells using the recombinant baculovirus 
system, and that VLPs of similar shape and size to the PRRSV virion are produced.  
These results will aid in further research of vaccine production using PRRSV VLPs. 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
INTRODUCTION 
 
Porcine reproductive and respiratory syndrome (PRRS), first observed in the 
United States in the late 1980s and in Europe the early 1990s, and is characterized by 
reproductive loses in sows and pneumonia and reduced growth in piglets. (Shi, M., Lam, 
T.T., et al. 2010).   PRRS has shown huge economic loses in the swine industry, with an 
estimated $664 million loss annually (Holtkamp, D.J., Kliebenstein, J.B., et al. 2013).  
These losses are not only due to direct production losses, but also from animal health 
costs for pharmaceuticals, biological, diagnostics, as well as prevention and treatment of 
secondary infections (Holtkamp, D.J., Kliebenstein, J.B., et al. 2013).   
The causative agent of PRRS is Porcine Reproductive and Respiratory Syndrome 
Virus (PRRSV), which is an enveloped positive strand RNA virus belonging to the 
family Arteriviridae, order Nidovirales, and primarily infects macrophages, especially 
porcine alveolar macrophages (PAMs), and dendritic cells, which are antigen presenting 
cells that play an important role in immune activation (Gorbalenya, A.E., Enjuanes, L., et 
al. 2006, Suarez, P. 2000).  PRRSV is easily transmitted through bodily fluids of pigs in 
close contact, and has been observed to be transmitted through the mosquito Aedes 
vexans and housefly Musca domestica, and therefore can move through a herd of pigs 
very easily (Otake, S., Dee, S.A., et al. 2003).   
When a pig is infected, the initial antibodies produced do not confer protection to 
the pig.  It is the neutralizing antibodies (NAs) to PRRSV structural protein, 
Glycoprotein-5 (GP5), that have been shown to provide protection and clear viremia.  
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Unfortunately, these NAs do not show up until 28 days post infection or later (Mateu, E., 
Diaz, I. 2008, Lopez, O.J., Osorio, F.A. 2004).  This gives the virus the ability to 
replicate and mutate while evading the host immune system, which leads us to the crucial 
feature of PRRSV infection: its ability to remain a persistent infection (PI); where the 
infected animal continues to shed virus, thus increasing the duration of transmission 
(Lopez, O.J., Osorio, F.A. 2004).  This feature of PRRSV is also of concern when using 
live attenuated vaccines, due to the fact that persistent infection can be re-activated, or 
they could become re-infected with the live attenuated vaccine (Murtaugh, M.P., 
Genzow, M. 2011, Nielsen, H.S., Oleksiewicz, M.B., et al. 2001).   
Currently, live attenuated vaccines and inactivated virus vaccines are 
commercially available for PRRSV; none of which confer heterologous protection, 
safety, or the ability to distinguish vaccinated pigs from non-vaccinated pigs (Kimman, 
T.G., Cornelissen, L.A., et al. 2009).  Attenuated vaccines have been shown to revert to 
virulence, spread from vaccinated to non-vaccinated individuals, produce infection, and 
recombine with field isolates (Murtaugh, M.P., Genzow, M. 2011, Nielsen, H.S., 
Oleksiewicz, M.B., et al. 2001).  Killed vaccines have been considered ineffective or of 
limited efficiency (Kimman, T.G., Cornelissen, L.A., et al. 2009, Murtaugh, M.P., 
Genzow, M. 2011).  Because of the possibility of severe reactions, resulting in an atypical 
PRRS complex of live attenuated vaccines, the ineffectiveness of the inactivated virus, 
and the overall lack of heterologous protection, a need for a cost-effective, heterologous 
protective vaccine is urgent.   
Virus-like particles (VLPs) are multiprotein complexes that mimic the virion 
structure, but lack the genetic material for reproduction.  Because VLPs lack genetic 
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material (non-structural proteins), PRRSV VLPs would be able to avoid the immune 
escape mechanism of non-structural proteins of PRRSV (Mateu, E., Diaz, I. 2008, Crisci, 
E., Barcena, J., et al. 2012, Miller, L.C., Laegreid, W.W. 2004).  VLPs are also easily and 
quickly manufactured, giving them the advantage over other vaccine options for the 
highly mutable PRRSV (Crisci, E., Barcena, J., et al. 2012, Noad, R., Roy, P. 2003).  
VLP vaccines have been shown to be safe, effective, and offer the ability to differentiate 
non-vaccinated from vaccinated individuals for several viruses, including human 
papilloma virus (HPV), hepatitis B virus (HBV), and bluetongue virus (BTV) (Noad, R., 
Roy, P. 2003, Crisci, E., Barcena, J., et al. 2012).   
The primary objectives of this study were to construct plasmids containing the 
GP4, GP5, and E genes of PRRSV that can be expressed in both mammalian and insect 
cells, to construct recombinant baculoviruses that express GP4, GP5, and E proteins of 
PRRSV for the purification of PRRSV VLPs and production VLPs similar in size and 
shape to PRRSV virions by expressing M, N, GP4, GP5, and E proteins simultaneously 
in insect cells. 
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LITERATURE REVIEW 
 
1. CLASSIFICATION AND EVOLUTION 
 Porcine reproductive and respiratory syndrome virus (PRRSV) belongs to the 
family Arteriviridae, under the order Nidovirales. Nidovirales consists of three other 
families, which include Coronaviridae, Roniviridae, and Toroviridae.  The viruses of 
Nidovirales are linear, positive sense, single-stranded RNA viruses that are enveloped 
and contain a 5’ cap structure as well as a 3’ poly (A) tail (Gorbalenya, A.E., Enjuanes, 
L., et al. 2006).  PRRSV belongs in the family Arteriviridae along with equine arteritis 
virus (EAV) of horses, lactate dehydrogenase-elevating virus (LDV) of mice, and simian 
hemorrhagic fever virus (SHFV) of monkeys.  Each of these viruses is species specific 
(Shi, M., Lam, T.T., et al. 2010). 
 PRRSV was first recognized to be the causative agent of porcine reproductive and 
respiratory syndrome (PRRS) in the late 1980s in the United States and in the early 1990s 
in Europe (Shi, M., Lam, T.T., et al. 2010).  Although the emergence was almost 
concurrent, the types of PRRSV are genetically different.  PRRSV Type 1 consists of 
viruses mainly from Europe, while PRRSV Type 2 consists of viruses mainly from 
Northern America and Asian countries.  The two types only share 55-70% nucleotide and 
50-80% amino acid similarity throughout the various PRRSV viral genes (Shi, M., Lam, 
T.T., et al. 2010). 
 There are two hypotheses as to the evolution of PRRSV pre-emergence.  The first 
hypothesis is that Type 1 and Type 2 diverged not long before emergence followed by an 
extremely high substation rate (Shi, M., Lam, T.T., et al. 2010).  Most RNA viruses 
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evolve at a rate of 10
-3
 to 10
-5
 per site per year, where PRRSV seems to have evolved at a 
rate of 10
-2
 per site per year (Hanada, K., Suzuki, Y, et al. 2005).  This hypothesis would 
put the estimated time of divergence for Type 1 and Type 2 PRRSV around 1972-1988, 
which is just before the virus seemed to have emerged (Hanada, K., Suzuki, Y, et al. 
2005).  According to this study, the evolutionary rate of PRRSV would be 4.71-9.8 x 10
-
2
, making it the highest among RNA viruses (Hanada, K., Suzuki, Y, et al. 2005).  The 
problem with this study, pointed out by Forsberg 2005, was the problematic methodology 
and the unproductive data set.   
This leads us to the second hypothesis that Type 1 and Type 2 diverged way 
ahead of the emergence and evolved independently on two continents for a long time 
(Shi, M., Lam, T.T., et al. 2010).  Forsberg used an alternative methodology and 
reanalyzed the existing data on PRRSV to conclude that the most recent ancestor, or 
tMRCA, or all PRRSV to be around 1880± 15 years (Forsberg, R. 2005).  The tMRCA of 
Type 1 is estimated to be around 1946-1967 and the tMRCA of Type 2 is estimated to be 
around 1977-1981.   
Both studies indicate that PRRSV originated from another host species, possibly 
wild boar, and was transmitted to swine within 10 years of the “original” outbreak of 
PRRS.   
The “original” outbreak of PRRS began in the late 1980s in the United States and 
in the early 1990s in Europe.  The first PRRSV Type 1 was isolated in the Netherlands 
and was termed the Lelystad virus because it formed highly homologous phylogenetic 
(Lelystad-like) clusters with other European samples (Shi, M., Lam, T.T., et al. 2010). 
More samples were collected and formed well-supported clads that had diverged prior to 
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the epidemic clad, which would indicate that they were not progenies of the Lelystad-like 
PRRSV and gave scientists the indication that Type 1 PRRSV viruses had been present in 
the field long before the “original” epidemic (Shi, M., Lam, T.T., et al. 2010).  There is 
an exceptionally large diversity and longer establishment of Type 1 PRRSV in Eastern 
Europe, but there seems to be a limited gene flow form Eastern Europe Type 1 PRRSV 
viruses to Western Europe Type 1 PRRSV (Shi, M., Lam, T.T., et al. 2010). 
In the late summer of 1996, an outbreak of “acute PRRS” emerged in southeast 
Iowa and several other states (Shi, M., Lam, T.T., et al. 2010).  This severe, acute PRRS 
resulted in elevated abortion rates and a slow mortality rate (Shi, M., Lam, T.T., et al. 
2010).  Of the herds affected by this PRRSV, many of them were vaccinated with 
Ingelvac PRRS MLV or both Ingelvac PRRS MLV and PrimePAC PRRSV, but the 
isolates of the acute PRRS were heterogenetic and very different from the isolates of the 
vaccines (Shi, M., Lam, T.T., et al. 2010). 
The next outbreak occurred in late 2001 and is termed the MN184 outbreak, due 
to the fact that the virus had Restriction Fragmented Length Polymorphism (RFLP) 1-8-4 
pattern and was identified as a highly virulent variant of PRRSV in the state of Minnesota 
(Shi, M., Lam, T.T., et al. 2010).  The MN184 outbreak has been hypothesized to have 
originated from Canada (Shi, M., Lam, T.T., et al. 2010). 
The most recent highly pathogenic outbreak of PRRSV occurred in China in the 
summer of 2006 causing prolonged high fever, red colorations on the body, and a high 
mortality rate in adult pigs (Shi, M., Lam, T.T., et al. 2010).   This highly pathogenic 
PRRSV spread for 12 months over more than 20 provinces in China and was believed to 
have evolved from the local diversity of PRRSV in China (Shi, M., Lam, T.T., et al. 
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2010).  It can be traced back to a single introduction from North America (Shi, M., Lam, 
T.T., et al. 2010).  
 
2. TRANSMISSION AND PATHOGENESIS 
 Direct routes or indirect routes can transmit PRRSV.  Direct transmission is 
accomplished through infected pigs via blood, semen, saliva, feces, aerosols, milk, 
colostrum, as well as vertical transmission of sow to piglet (Cho, J.G., Dee, S.A., 2006).  
One study in England showed PRRSV could be transmitted up to 3 kilometers by aerosol 
(Cho, J.G., Dee, S.A., 2006).  Another study has shown pathogenicity of the isolate to be 
more of a factor for aerosol transmission.  The PRRSV MN-184 isolate, a highly 
pathogenic isolate that produces a higher viral load in blood and tissues with clinical 
symptoms that are more severe and of longer duration, was observed to be transmitted via 
aerosol, while PRRSV MN-30100, an isolate with low pathogenicity, was unable to be 
transmitted via aerosol in this study (Cho, J., Deen, J., et al. 2007).  Clinical symptoms of 
PRRSV MN-30100 are mild and the viral concentration in blood and tissue is lower than 
more pathogenic strains (Cho, J., Deen, J., et al. 2007). 
 Several indirect routes of PRRSV transmission, including formites, transport 
vehicles, and insects, have been observed.  Needle sharing, as well as, contaminated 
boots and coveralls can transmit PRRSV (Cho, J.G., Dee, S.A., 2006).  According to 
Otake, S, Dee, S.A., et al 2002, when following the “biosecurity protocols”, transmission 
can be minimized, if not eliminated.  “Biosecurity protocols” enforced during this study 
included combinations of hand washing, changing or discarding clothing and footwear, 
showering into and out of facility, and refraining from contact with swine for 12-72 hours 
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before entering the facility.  PRRSV and PRRSV antibodies were not detected at any 
time during the study after the protocol (Otake, S, Dee, S.A., et al 2002).   
Transmission via transport vehicles of pigs has also been observed.  Because of 
the properties of PRRSV: its survivability outside the host is affected by temperature 
(viability decreases with increased temperatures), pH (infectivity is reduced when pH is 
less than 6.0 or greater than 7.65), and exposure to detergents (decreased infectivity with 
lipid solvents, chloroform, and ether); transmission via transport vehicles can be 
minimized (Cho, J.G., Dee, S.A., 2006).  After drying and sanitizing transport vehicles, 
risk of infection was reduced (Cho, J.G., Dee, S.A., 2006). 
Although insects, including mosquitoes (Aedes vexans) and houseflies (Musca 
domestica), are not biological vectors of PRRSV, transmission of PRRSV can be 
accomplished if viral load post-ingestion and environmental temperatures are optimal 
(Otake, S., Dee, S.A., et al. 2003).  In one study, PRRSV isolated from infected recipient 
pigs was found to be 100% homologous with donor pig after nucleic-acid sequencing, 
indicating transmission of PRRSV from infected swine to non-infected swine via 
mosquito was successful (Otake, S., Dee, S.A., et al. 2002).   
Avian and non-porcine mammalian species, including rodents, raccoons, dogs, 
cats, opossums, skunks, house sparrows, and starlings, have not been found capable of 
transmitting PRRSV (Cho, J.G., Dee, S.A., 2006). 
Once infected with PRRSV, sows begin to show inappetence and anorexia, with 
reproductive symptoms progressing to abortion, premature birth, late term abortion 
(around 107-112 days), increased incidence of fresh or autolytic stillborn, fetal death with 
or without mummification, and weak born piglets that die shortly after birth (Nodelijk, G. 
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2011, Wensvoot, G. 1993, Rossow, K.D., Collins, J.E., et al 1995).  Other clinical 
symptoms of sows can include transient discoloration (cyanosis) of ears, abdomen, and 
vulva, respiratory distress, and slightly elevated body temperatures (Nodelijk, G. 2011, 
Wensvoot, G. 1993) 
Respiratory disorders manifest in piglets infected shortly after birth and include 
clinical symptoms of anorexia, transient fever, respiratory distress, roughened hair coats, 
slow growth, interstitial pneumonia, respiratory disease, and sometimes death (Wensvoot, 
G. 1993).  Older piglets or fattened piglets seem less affected by PRRSV and show 
shorter periods of anorexia and mild respiratory distress (Wensvoot, G. 1993).  Disease 
symptoms tend to be aggravated by secondary infections, especially in neonatal pigs with 
PRRSV pneumonia (Wensvoot, G. 1993, Nodelijk, G. 2011).  As PRRSV becomes 
established in a herd, the number of abortions decrease, and infection manifests mostly in 
weaned and growing pigs (K.D., Collins, J.E., et al 1995).   
Gross and/ or microscopic lesions can be seen in lymph nodes, lungs, heart and 
blood vessels; therefore PRRS could be considered a multisystem disease (K.D., Collins, 
J.E., et al).   
Boars shed PRRSV in semen and can therefore be a cause of infection during 
coitus (K.D., Collins, J.E., et al 1995).  
Clinical symptoms in sows and piglets led to the multitude of names including, 
Mystery Swine Disease, Swine Infertility and Respiratory Syndrome (SIRS), Porcine 
Epidemic Abortion and Respiratory Syndrome (PEARS), Seuchenhafter Spatabort 
Schweine, Abortus Blauw, and Blue-eared Pig Disease, which ultimately led to the 
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current name Porcine Reproductive and Respiratory Syndrome (PRRS) (Nodelijk, G. 
2011).   
The crucial feature of PRRSV infection is its ability to remain a persistent 
infection (PI), where the infected animal continues to shed virus, thus increasing the 
duration of transmission (Lopez, O.J., Osorio, F.A., 2004).  Early, or acute, PI follows 
initial exposure to PRRSV, which is characterized by mentioned clinical symptoms, as 
well as abundant replication in alveolar macrophages and other tissue macrophages 
(Lopez, O.J., Osorio, F.A., 2004, Allende, R., Laegreid, W.W., et al 2000).  Acute PI may 
last up to one month and is characterized by high viral loads in tissues and presence of 
cell-free viremia (Lopez, O.J., Osorio, F.A., 2004).  Low levels of viral replication and 
low PRRSV load levels in lymph nodes and tonsils, sites of replication, are easily 
recovered during the late infectious phase of PI (Lopez, O.J., Osorio, F.A., 2004, 
Rowland, R.R.R., Lawson, S., et al. 2003).  One study showed no evidence of virus in 
lung or other non-lymphoid organs during PI (Rowland, R.R.R., Lawson, S., et al. 2003).  
Viremia peeks between 0-1 month and can last up to 2 months, which is followed by a 
total antibody response that can last up to a year or longer (Lopez, O.J., Osorio, F.A., 
2004).  Viral load in tissues begins to increase around 7-9 days post infection and begins 
a steady decrease around 5 months post infection (Lopez, O.J., Osorio, F.A., 2004, 
Allende, R., Laegreid, W.W., et al 2000).  This corresponds with the appearance of 
Neutralizing Antibodies (NAs) and Interferon λ (INF-λ) producing cells which 
exponentially increases (Lopez, O.J., Osorio, F.A., 2004).  PRRSV is eventually cleared 
from the body at around 150 days post infection (Lopez, O.J., Osorio, F.A., 2004, 
Allende, R., Laegreid, W.W., et al 2000).   
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PRRSV has been shown to cause apoptosis in infected and non-infected 
macrophages, monocytes, germ cells, and cells of endometrium/ fetal placentas, which 
peaks at 14 days post infection, and is preceded by a peak in interleukin-10 (IL-10) and 
interleukin-1 (IL-1) production (Labarque, G., Van Gucht, S., et al 2003, Sur, J.H., 
Doster, A.R., et al. 1998 Karniychuk, U.U., Saha, D., et al. 2011).  There is also evidence 
PRRSV interferes with cellular innate immune responses, which are closely tied with 
apoptosis (Miller, L.C., Fox, J.M. 2004).  The interference of host immune responses 
contributes to the risk of secondary infections to PRRSV.  There is an increased severity 
of clinical disease in animals co-infected with PRRSV and different bacteria, including 
Streptococcus suis, Haemophilus parasuis, Salmonella choleraesuis, Mycoplasma 
hyopneumoniae.  (Thanawongnuwech, R., Brown, G.B., et al 2000).  One explanation of 
PRRSV infected animals increased susceptibility to S. suis could be PRRSV induces 
suppression of pulmonary intravascular macrophage function (Thanawongnuwech, R., 
Brown, G.B., et al 2000).   
 
3. GENOME ORGANIZATION 
 The PRRSV 15kb long RNA genome is capped at the 5’ end and polyadenylated 
at the 3’ end (Kim, W., Yoon, K. 2008).  The genome encodes at least nine open reading 
frames (ORFs), each of which is expressed via the generation of a 3’- co-terminal nested 
set of subgenomic mRNA (Kim, W., Yoon, K. 2008).  ORF 1a and 1b make up about 
80% of the genome and encode the RNA-dependent RNA polymerase, aka RNA 
replicase, and non-structural proteins (nsps) (Meulenberg, J.J.M. 2008).  ORF1a is 
translated directly from genomic RNA, while the ribosomal frameshifting 5’ end of the 
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genome expresses ORF1b (Den Boon, J.A., Faaberg, K.S., et al. 1995, Dokland, T. 
2010).    The two large ORFs, ORF1a and ORF1b, encode two multidomain replicase 
polyproteins, pp1a and pp1ab (Sun, Y., Xue, F., et al 2009, Dokland, T. 2010).  These 
polyproteins are processed by viral proteases to yield at least 14 non-structural proteins 
(Dokland, T. 2010, Sun, Y., Xue, F., et al 2009).  First, nsp1α, nsp1β, and nsp2 
(proteases) release themselves from pp1a, and then nsp4 (the fourth protease) cleaves the 
remaining nsps from the polyproteins (Dokland, T. 2010, Sun, Y., Xue, F., et al 2009).  
Remaining nsps include the RNA-dependent RNA polymerase (nsp9), a helicase (Hel/ 
nsp 10), and a Xenopus Laevis homolog poly (u), which is an endonuclease (nsp11) 
(Dokland, T. 2010, Sun, Y., Xue, F., et al 2009).  These nsps form a replication/ 
transcription complex essential for viral RNA synthesis (Sun, Y., Xue, F., et al 2009).   
 ORFs 2-7 are located at the 3’ end of the genome and encode the structural 
proteins that are associated with the PRRSV virion (Meulenberg, J.J.M. 2008).  These 
ORFs are expressed from the 3’ nested set of subgenomic mRNAs synthesized during 
PRRSV replication, and are composed of a leader sequence that is derived form the 5’ 
end of the viral genome (Meulenberg, J.J.M. 2008).  ORF2b is completely embedded 
within ORF2a and encodes a non-glycosylated, minor structural protein, Envelope (E) 
(Meulenberg, J.J.M. 2008, Kim, W., Yoon, K. 2008).  ORF2a, ORF3, and ORF4, encode 
N-glycosylated minor envelope proteins Glycoprotein-2a (GP2a), Glycoprotein-3 (GP3), 
and Glycoprotein-4 (GP4), respectively (Kim, W., Yoon, K. 2008, Meulenberg, J.J.M. 
2008).  GP2a, GP3, and GP4 form heterotrimers by disulfide linkages (Kim, W., Yoon, 
K. 2008).  Major envelope protein, Glycoprotein-5 (GP5), which was previously known 
as Envelope, is encoded by ORF5 and forms heterodimers with the major protein 
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Membrane (M) that is encoded by ORF6 (Kim, W., Yoon, K. 2008).  This GP5/ M 
heterodimer dominates the virion surface (Kim, W., Yoon, K. 2008).  Nucleocapsid (N) 
protein, another major structural proteins expressed from ORF7, is the first antigen that 
produces a non-neutralizing antibody response in pigs during early infection (Kim, W., 
Yoon, K. 2008).   
 
4. VIRION STRUCTURE 
 PRRSV virion structure is spherical or oval in shape and ranges from 50-74 nm in 
diameter, with 54nm being the median (Dokland, T. 2010).  Using electron microscopy 
(EM), as well as X-ray crystallography, a smooth outline with a few protruding features 
can be observed (Dokland, T. 2010).  The protruding features are thought to be small 
ectodomains, about 2nm, of the major envelope proteins M, 18-19kDa, and GP5, 25kDa 
heterodimer with approximately 16 and 30 residues, respectively (Dokland, T. 2010, Dea, 
S., Gagnon, C.A., et al. 2000).  This interaction between GP5-M is required for proper 
post-translational processing of proteins (Das, P.B., Dinh, P.X., et al. 2009).  The lipid 
bilayer envelope has a thickness of approximately 4.5nm and some cross-striations can be 
observed in the membrane, which are assumed to correspond to envelope (E) protein 
transmembrane (TM) domains (Dokland, T. 2010).  E protein possesses ion-channel-like 
properties that may function as a viroporon on the envelope as well, which may account 
for the striations observed (Das, P.B., Dinh, P.X., et al. 2009).  There are also a few 
protruding features from the membrane surface, about 10-15nm, which are most likely 
the less abundant, more bulky membrane proteins, GP2 for example (Dokland, T. 2010).  
The GP2-GP3-GP4 heterotrimer, 29kDa, 31kDa, and 42kDa, respectively, has 436 
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residues on the outside membrane, which are a 5-10nm structure (Dokland, T. 2010, 
Gagnon, C.A., et al. 2000).  There has also been a strong interaction between GP4 and 
GP5 observed, as well as in interaction of GP2a and GP4 with CD163 (Das, P.B., Dinh, 
P.X., et al. 2009).  GP4 is critical for mediating interglycoprotein interactions, and serves 
as a viral attachment protein that is responsible for mediating interactions with CD163 for 
virus entry into susceptible cells, along with GP2a (Das, P.B., Dinh, P.X., et al. 2009). 
 The internal core, whose size and shape correspond with its envelope, has an 
average diameter of 39 nm and is separated from the envelope by a 2-3nm gap (Dokland, 
T. 2010).  The gap is transversed by only a few strands of density, which means that the 
interactions between the internal core and the envelope are weak and flexible (Spilman, 
M.S., Welbon, C., et 2009).  The core is a 12nm thick double layer that surrounds a less 
dense area, indicating there is a hollow core (Dokland, T. 2010).  N protein, 15kDa, 
which is the most abundant protein expressed in infected cells with 1415 copies, 
comprises the Nucleocapsid, or internal core (Spilman, M.S., Welbon, C., et 2009, 
Dokland, T. 2010, Gagnon, C.A., et al. 2000).   This 123-128 amino acid protein, the 
smallest subgenomic mRNA, interacts with viral RNA to form the viral nucleocapsid 
(Dokland, T. 2010).  It is the most immunogenic protein, but produces antibodies that are 
non-neutralizing and non-protective (Dokland, T. 2010).  Rather than having an 
icosahedral shell, the nucleocapsid has been thought to be helical and filamentous 
(Spilman, M.S., Welbon, C., et 2009).  One possible model for the nucleocapsid structure 
is that the N protein forms dimers that form two layers to make a linked, twisted chain 
with the viral RNA in the middle (Spilman, M.S., Welbon, C., et 2009).  The chain then 
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interacts with the N-terminal RNA-binding domain of N and is bundled into a roughly 
spherical shape with a hollow interior (Spilman, M.S., Welbon, C., et 2009).   
 
5. PRRSV LIFE CYCLE 
 PRRSV prefers to infect porcine alveolar macrophages (PAMs) that have been 
recently activated, but has also been known to infect monocytes, glial cells, porcine 
pulmonary cells, and macrophages of other tissues, including intravascular cells, 
endothelial cells, smooth muscle cells and fibroblasts (Suarez, P. 2000).   
The virus must enter the cell for the cell to become infected.  PRRSV particles 
have been seen at the cell surface with virus particles then observed within small vesicles 
circumcised by a clathrin-like zone, but no virus particles have been detected fusing at 
the plasma membrane; therefore, receptor mediated endocytosis must be involved 
(Kreutz, L.C., Ackermann, M.R. 1996).   
The first step for PRRSV entry is attachment.  PRRSV GP5-M heterodimer on the 
viral envelope attaches to heparin sulfate glycosaminoglycan (GAGs) present on 
macrophage surface (Delputte, P.L., Costers, S., et al. 2005).  Heparin sulfate GAGs are 
found in different tissues, as well as macrophages, therefore binding to non-permissive 
cells occurs (Van Breedam, W., Van Gorp, H., et al 2010).  One study showed that 
washing cells, that had PRRSV attached, with heparin could remove viral attachment 
early, but not at a later time (Delputte, P.L., Costers, S., et al. 2005).  This showed that 
there is another interaction with a receptor that takes place. 
An interaction with a porcine sialoadhesion receptor (pSn) and GP5-M follows 
the attachment of PRRSV to heparin sulfate GAGs (Van Breedam, W., Van Gorp, H., et 
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al 2010, Delputte, P.L., Costers, S., et al. 2005, Van Breedam, W., Van Gorp, H., et al. 
2010).  pSn binds to the sialic acid of GP5, and the pSn-GP5-M interaction is critically 
dependent on the sialic-acid binding capacity of pSn as well as on sialic acids on viral 
GP5 glycoprotein (Van Gorp, H., et al. 2010).  The pSn is macrophage restricted 
(Delputte, P.L., Costers, S., et al. 2005).  Upon binding of the virus to the pSn receptor, 
the virus is internalized via the mechanism of clathrin-mediated endocytosis and enters 
the endocytic pathway (Van Breedam, W., Van Gorp, H., et al 2010, Delputte, P.L., 
Vanderheijden, N., et al. 2002, Delputte, P.L., Costers, S., et al. 2005).  Fusion does not 
occur between the endosomal membrane and viral envelope (Delputte, P.L., Costers, S., 
et al. 2005).  For proper virus replication and for genome release into the cytoplasm of 
target cells, a drop in pH in the endosome is required (Delputte, P.L., Vanderheijden, N., 
et al. 2002, Van Breedam, W., Van Gorp, H., et al 2010).   
Once the virus has been internalized, the viral genome is released from the early 
endosome and into the cytoplasm of host cells (Van Breedam, W., Van Gorp, H., et al 
2010).  PRRSV virions do not continue to late endosomes (pH 5.0-6.0) or lysosomes (pH 
4.6-5.0) (Van Breedam, W., Van Gorp, H., et al 2010).  CD163, a putative PRRSV 
scavenger receptor, is essential for the genome release, and may do so by interactions 
with GP2a and GP4 (Van Breedam, W., Van Gorp, H., et al 2010, Calvert, J.G., Slade, 
D.E., et al. 2007, Van Gorp, H., Van Breedam, W., et al 2008).  PRRSV is uncoated 
through this process, as well as by different cellular proteases, membrane protein E, and 
serine proteases (Van Breedam, W., Van Gorp, H., et al 2010).  More research is needed 
in this area to determine the exact functions of these proteins.   
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Initiation of transcription and translation is next required for the formation of new 
virions.  PRRSV genome is expressed through subgenomic transcripts (mRNA1-
mRNA7), each of which encodes PRRSV ORFs (Conzelmann, K., Visser, N., et al. 
1992).  The translation of ORF1a and expression through a ribosomal frame shift of 
ORF1ab yield the pp1a and pp1ab polyproteins, respectively, that are then processed 
extensively by ORF1a encoded viral proteases, yielding at least 14 PRRSV NSPs (Sun, 
Y., Xue, F., et al. 2009, Dokland, T., 2010).  Four proteases (NSP1α, NSP1β, NSP2, and 
NSP4), the RNA-dependent RNA polymerase (NSP9), a helicase (NSP10, and an 
endonuclease (NSP11) are included in the expressed NSPs (Dokland, T., 2010).  NSP1α 
and NSP1β are at the N-terminus of pp1a, each including a papain-like cysteine protease 
domain called PCPα and PCPβ, respectively, and cleave themselves from the polyprotein 
in their C-terminal junctions (Dokland, T., 2010).  NSP1β is cleaved from NSP2 auto 
catalytically by PCPβ, followed by the papain-like protease (PL2) of NSP2 cleaving at 
the NSP2-3 junction (Dokland, T., 2010).  NSP4, the “main” viral protease, carries out 
the remaining cleavages in both pp1a and pp1ab, which is activated upon the cleavage by 
the NSP2 protease at the NSP2-3 junction (Dokland, T., 2010).  The cleavage products of 
pp1a, NSP5-8, are not well described, while the cleavage products contained within 
pp1ab, NSP9-11, are the most conserved with the nidoviruses (Dokland, T., 2010).   
OFRs 2-5 encode glycosylated membrane proteins GP2-GP5, ORF6 encodes non-
glycosylated M protein, and ORF7 encodes the N protein (Dokland, T., 2010).  ORF2b is 
fully enclosed with ORF2, and encodes the E protein, or GP2b, which is non-
glycosylated (Dokland, T., 2010).   
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N protein forms homodimers through covalent and non-covalent interactions, and 
is distributed between cytoplasmic and nuclear compartments (Rowland, R.R.R., Yoo, D. 
2003).  Covalent interactions are formed through disulfide linkages, while the non-
covalent region holds two basic regions, nuclear localization signal 1 (NLS-1), and 
nuclear localization signal 2 (NLS-2) (Rowland, R.R.R., Yoo, D. 2003).  NLS-1 and 
NLS-2 are important for the packaging of viral RNA genome within the nucleocapsid of 
the virus (Rowland, R.R., Kervin, R., et al. 1999).  Vesicles containing enveloped 
nucleocapsids are derived from the endoplasmic reticulum, and then transported to the 
premedial Golgi apparatus, where viral budding takes place and virus particles are 
released (Suarez, P. 2000).  This budding and accumulation of enveloped particles can 
only be observed between the smooth ER and the medial Golgi, where the virions seem 
to mature (Suarez, P. 2000).  The virus assembly is completed when the enveloped 
particles interact with the N protein in the cytosol and are transported to the plasma 
membrane (Suarez, P. 2000, Wissink, E.H.J., Krose, M.V., et al. 2005).   
 
6. PRRSV IMMUNOLOGY 
 PRRSV immunology has been a challenge and is not fully understood.  
Infected pigs develop a strong humoral response 5-7 days post infection (pi), with IgM 
antibodies reaching a peak at day 14 pi and declining to undetectable levels by day 42 pi, 
and IgG antibodies reaching a maximum at 21-49 days pi (Mateu, E., Diaz, I. 2008, 
Lopez-Fuertes, L., Campos, E., et al 2000).  Although the response is strong, these 
antibodies are non-neutralizing and do not confer any sort of protection against PRRSV 
(Mateu, E., Diaz, I. 2008).  These early antibodies may aid in the development of PRRS 
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by enhancing internalization and viral replication in alveolar macrophages (Mateu, E., 
Diaz, I. 2008).  The earliest antibodies are to the N protein, followed by the M protein, 
and finally to the GP5 protein (Mateu, E., Diaz, I. 2008).  Neutralizing antibodies (NAs), 
which appear 28 days pi or later, are mainly directed against the neutralization epitope 
(NE) in the ectodomain of GP5, which correlates with the clearance of viremia (Mateu, 
E., Diaz, I. 2008, Lopez-Fuertes, L., Campos, E., et al 2000).  Other proteins that may 
contain a neutralizing epitope include GP4 and M (Mateu, E., Diaz, I. 2008).  One of the 
challenges of immunology with PRRSV is its ability to mutate; with the NE being a 
typical candidate for mutation, although NEs can be located within a region of pathogenic 
function, in which case, the virus would need to find other means to evade the immune 
system (Lopez-Fuertes, L., Campos, E., et al 2000).  This mutation is a typical 
mechanism of RNA viruses is called antigenetic drift.  PRRSV can use a decoy epitope, 
as well as sugars surrounding the NE, to hinder the response to NE, which could account 
for the late appearance of NAs (Lopez-Fuertes, L., Campos, E., et al 2000).  NAs alone 
have been found to fully prevent transplacental infection, as well as infection in pregnant 
sows (Lopez-Fuertes, L., Campos, E., et al 2000).   
 Interferons and cytokines are also important for protection from and removal 
of PRRSV.  A strong lymphocyte proliferative response can be seen around four weeks 
pi, which would parallel with appearance of NAs (Mateu, E., Diaz, I. 2008).  One study 
showed that interferon γ (INF-γ) starts no sooner than four weeks pi and builds until the 
virus is eliminated, which coincides with PRRSV specific INFγ and NA appearance 
(Lopez-Fuertes, L., Campos, E., et al 2000).  According to Miller, L.C., Laegreid, W.W., 
2004, PRRSV infection directly interferes with type 1 interferon transcriptional activation 
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at the level of interferon β (INF-β), which is early in its pathway. Type 1 interferons are 
synthesized and secreted by eukaryotic cells in response to viral infections, and PRRSV 
is highly susceptible to type 1 interferons. They found low levels, if any, interferon α 
(INF-α), an interferon that is synthesized following INF-β synthesis and secretion, in the 
lungs or in-vitro infected alveolar macrophages of PRRSV-infected pigs (Miller, L.C., 
Laegreid, W.W., 2004).  Type 1 interferons are inhibited by another cytokine, interleukin 
10 (IL-10) (Mateu, E., Diaz, I. 2008).  IL-10 is a powerful cytokine that downregulates 
host immune responses and several proinflammatory cytokines, including tissue necrosis 
factor α (TNF-α) and INF-α (Suradhat, S., Thanawongnuwech, R., et al. 2003).  Levels of 
IL-10 increase in pig peripheral blood macrophage cells (PBMCs) and pig lungs after 
PRRSV infection while levels of INF-γ expression decrease, which seems consistent 
among intracellular pathogens that target macrophage (Mateu, E., Diaz, I. 2008, 
Suradhat, S., Thanawongnuwech, R., et al. 2003).  IL-10 may also have an inhibitory 
effect on the function of antigen presenting cells (APCs), which could contribute to the 
delayed induction of protective immune response to PRRSV (Suradhat, S., 
Thanawongnuwech, R., et al. 2003).  IL-10 inhibits the production of cytokines and 
proliferation of CD4
+
 cells, which results in the inhibition and activation of T cells, and 
in turn interferes with cell-mediated immune responses and correct antigen presentation 
(Suradhat, S., Thanawongnuwech, R., et al. 2003, Mateu, E., Diaz, I. 2008).  PRRSV also 
down-regulates the expression of MHC-I and MHC-II in monocyte-derived dendritic 
cells (Mateu, E., Diaz, I. 2008).  The effect of this under-expressed, down-regulated 
immune system is a delayed response to the virus, which results in clinical manifestation 
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and shedding of virus for longer periods of time, and therefore more spreading of PRRSV 
and deaths. 
  
7. CURRENT VACCINES 
 There are currently several types of vaccines available for PRRSV; they 
include, live attenuated, killed, and subunit vaccines, none of which function ideally for 
PRRSV.  They are unable to completely prevent respiratory infection, transplacental 
transmission, or pig-to-pig transmission (Kimman, T.G., Cornelissen, L.A., et al. 2009).  
Challenges faced when producing a vaccine include effectiveness, heterogeneity, safety, 
cost, and differentiation of vaccinated versus naturally infected animals.  The North 
American and European strains of PRRSV are clinically, antigenetically, and genetically 
heterogeneous, and isolates within each genotype differ by approximately 20%, with GP5 
being the most variable, and most immunogenic (Kimman, T.G., Cornelissen, L.A., et al. 
2009).  The evolution of PRRSV by random mutation and intragenic recombination 
events also adds to the difficulty of producing an effective vaccine (Kimman, T.G., 
Cornelissen, L.A., et al. 2009).   
 Attenuated vaccines are live viruses derived by cell culture attenuation of 
virulent isolates (Murtaugh, M.P., Genzow, M. 2011).  PRRSV live attenuated vaccines 
have been shown to revert to virulence under field conditions, spread from vaccinated to 
non-vaccinated, produce lung and lymphoid tissue infections, and maintain infection for 
periods of time (Murtaugh, M.P., Genzow, M. 2011, Nielsen, H.S., Oleksiewicz, M.B., et 
al. 2001).  Natural recombination between attenuated vaccine strains and field strains has 
also been found to occur, which could affect PRRSV evolution (Li, B., Fang, L., et al. 
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2009).  There has been evidence of some immune protection with attenuated vaccines, 
but this has been in homologous situations, and the risks outweigh any immune 
advantages (Kimman, T.G., Cornelissen, L.A., et al. 2009).   
 Killed vaccines are inactivated preparations of virulent isolates that may 
reduce levels of viremia in some pigs, but have ultimately been considered ineffective or 
of limited efficiency at best (Kimman, T.G., Cornelissen, L.A., et al. 2009, Murtaugh, 
M.P., Genzow, M. 2011).  In trials, there has been no consistent benefit against infection 
or respiratory disease (Murtaugh, M.P., Genzow, M. 2011).   
 Subunit vaccines express only selected proteins and they allow the immune 
system to be focused on protective B cell and/ or T cell epitopes of a particular viral 
protein (Hu, J., Ni., Y., et al. 2012, Murtaugh, M.P., Genzow, M. 2011).  They eliminate 
any safety concern of virulent reversion of modified live vaccines, but being based on 
recombinant proteins can suffer poor immunogenicity due to incorrect folding of target 
protein or poor presentation to the host immune system (Noad, R., Roy, P. 2003 Hu, J., 
Ni., Y., et al. 2012).  Subunit vaccines are more costly due to the fact that more doses of 
increases concentration of antigen are needed to offer protection (Hu, J., Ni., Y., et al. 
2012).   
 A vaccine that can provide protection against PRRSV by neutralizing virus 
entry, can offer heterologous protection without reversion or recombination, and can be 
differentiated from field strains, would be the ideal candidate for vaccine production. 
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8. VIRUS LIKE PARTICLES AS VACCINE CANDIDATES 
 Virus-like particles (VLPs), for use as vaccines, have been produced for over 
30 different viruses that infect humans and animals (Noad, R., Roy, P. 2003).  VLPs are a 
specific class of subunit vaccines that do not contain infectious genetic material while 
mimicking the structure of authentic virus particles (Noad, R., Roy, P. 2003, Crisci, E., 
Barcena, J., et al. 2012).  They are easily recognized by host immune system and are able 
to present viral antigen with a more authentic conformation than other subunit vaccines 
(Noad, R., Roy, P. 2003).  VLPs are based on an expression system of viral capsid 
proteins that lead to spontaneous assembly of virus particles that are structurally similar 
to authentic viruses (Noad, R., Roy, P. 2003). There are several advantages of VLPs for 
vaccine use over current vaccines available. 
 A well-defined geometry and uniformity with repetitive and ordered surface 
structures that mimic the overall structure of authentic virions is one major advantage of 
VLPs (Crisci, E., Barcena, J., et al. 2012).  Using a recombinant expression system, 
multiple copies of one or more major viral capsid or envelope proteins are overexpressed 
to self-assemble into VLPs (Noad, R., Roy, P. 2003, Crisci, E., Barcena, J., et al. 2012).  
These particles lack DNA or RNA, but have the authentic viral capsid or envelope 
proteins that are seen in attenuated or inactivated vaccines, and therefore lack the 
drawbacks of recombination, virus replication, insertion, re-assortment or reversion, and 
are much safer than attenuated or inactivated vaccines (Crisci, E., Barcena, J., et al. 2012, 
Noad, R., Roy, P. 2003). Because VLPs are only structural proteins that do not contain 
DNA, RNA, or NSPs, they are able to be differentiated from a field infection and have 
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the possibility to follow Differentiating Infected from Vaccinated Animals (DIVA) 
compliance (Crisci, E., Barcena, J., et al. 2012). 
 VLPs have a particulate and multivalent nature while being able to preserve 
the native antigenic conformation of virions, and can trigger the innate immune system 
by being recognized by toll-like receptors (TLRs) and pattern-recognition receptors 
(PRRs), as well as stimulate a strong B-cell, CD4
+
 T cell proliferative responses and 
cytotoxic T cell responses (Crisci, E., Barcena, J., et al. 2012, Noad, R., Roy, P. 2003).  
The antigens are highly stable when compared to soluble antigens in extreme 
environmental conditions (Crisci, E., Barcena, J., et al. 2012).   
 There are several different expression systems that can be used to produce 
VLPs.  The most popular is recombinant baculovirus expression in insect cells, but 
bacteria, yeast, mammalian, and plant cells have also been used (Crisci, E., Barcena, J., et 
al. 2012).  The major advantages of using the recombinant baculovirus expression system 
are that large amounts of correctly folded recombinant proteins are produced in 
eukaryotic-like post-translational modifications with a high recovery of correctly folded 
antigens, the complexity of VLPs produced is higher than in yeast or bacterial cells, there 
is a limited host range (insects) and is therefore safe for vertebrates, the method is simple, 
fast for large grade vaccine production, and provides high versatility, which is very 
important because of the highly mutable surface proteins of viruses.  (Crisci, E., Barcena, 
J., et al. 2012, Noad, R., Roy, P. 2003).  A disadvantage to the recombinant baculovirus 
expression system is the possibility of contaminated virions, but the use of chemical 
treatment or the use of a recombinant baculovirus lacking the vp80 gene, the gene that is 
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essential for virus formation, can easily eliminate that problem and will not affect foreign 
gene expression (Crisci, E., Barcena, J., et al. 2012, Noad, R., Roy, P. 2003).   
 Several VLPs have been produced for various viruses, and some are even used 
in practice today.  The hepatitis B virus and human papilloma virus are both human 
viruses that have VLP vaccines produced from the expression of the S gene in yeast and 
the expression of the L1 protein in both insect or yeast cells, respectively (Harro, C.D., 
Pang, Y.S., et al. 2001 Noad, R., Roy, P. 2003).  Ebola VLPs have also been produced by 
expressing VP40 or GP proteins using the recombinant baculovirus expression system in 
insect cells (Ye, L., Lin, J., et al. 2006).  Animal VLP vaccines have also been produced, 
and include porcine circovirus type 2 (PCV2), canine parvovirus (CPV) and bluetongue 
virus (BTV).  CPV overexpresses its VP2 gene and assembles in insect cells, where BTV 
overexpresses four major structural proteins, VP2, PV2, PV5, and VP9 using the 
recombinant baculovirus expression system (Stewart, M., Dovas, C.I., et al. 2012, Noad, 
R., Roy, P. 2003).  The four proteins are co-expressed in the same cell and form VLPs 
structurally indistinguishable from virus particle VLPs, only lacking the genome (Noad, 
R., Roy, P. 2003).  
 Influenza is another candidate for VLP vaccine production.  Its major 
structural protein, M1, has been shown to be sufficient to produce VLPs, but M1-HA and 
M1-HA-NA VLPs have been shown to confer protection from lethal challenge of the 
same type of Influenza virus (Roy, P., Noad, R. 2008).   
 Not only are VLPs used for vaccines, but they can be used in research as well.  
Norwalk virus is unable to be grown in cell culture, so scientists use VLPs to monitor the 
disease (Noad, R., Roy, P. 2003).  Norwalk virus VLPs have also been shown to be 
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effective at stimulating IgG, IgA, and humoral responses in mice, and could therefore be 
a potential vaccine.   
 With the nature of PRRSV and the previous research done on VLPs, PRRSV 
seems to be an ideal candidate for VLP vaccine production. 
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CHAPTER 2: VIRUS-LIKE PARTICLES GENERAGED BY EXPRESSING 
PROTEINS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME 
VIRUS (PRRSV) USING THE RECOMBINANT BACULOVIRUS EXPRESSION 
SYSTEM  
 
INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV) belongs to the 
family Arteriviridae, and is a linear, positive sense, single-stranded, enveloped RNA 
virus (Gorbalenya, A.E., Enjuanes, L., et al 2005).  PRRSV genome encodes at least nine 
open reading frames (ORF), which express at least 14 non-structural proteins and seven 
structural proteins (Meulenberg, J.J.M. 2000, Dokland, T. 2010).  The seven structural 
proteins form the spherical or oval virion, with the nucleocapsid (N) protein, membrane 
(M) protein, and glycoprotein 5 (GP5) being the major structural proteins (Dokland, T. 
2010).  The M and GP5 proteins are essential for viral attachment and entry into 
susceptible porcine cells (Delputte, P.L., Costers, S., et al. 2005).  N protein is the most 
abundant protein expressed in infected cells and is the most immunogenic (Spilman, 
M.S., Welbon, C., et 2009, Dokland, T. 2010, Gagnon, C.A., et al. 2000).  GP4 is critical 
for mediating interglycoprotein interactions, and serves as a viral attachment protein that 
is responsible for mediating interactions with CD163 for virus entry into susceptible 
cells, along with GP2a (Das, P.B., Dinh, P.X., et al. 2009). E protein possesses ion-
channel-like properties that may function as a viroporon on the envelope (Das, P.B., 
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Dinh, P.X., et al. 2009).   Virion assembly and budding then take place in the 
endoplasmic reticulum and Golgi apparatus of host cells (Suarez, P. 2000).   
 Clinical symptoms of PRRSV infected pigs range from respiratory distress of 
piglets to reproductive failure in sows, and may reduce the annual production of a herd by 
15% (Wensvoot, G. 1993, Holtkamp, D.J., Kliebenstein, J.B., et al 2013).  The crucial 
feature of PRRSV infection is its ability to remain persistent.  Animals continue to shed 
virus during persistent infection (PI), thus continuing to transmit virus, and increase the 
likelihood of contracting a secondary infection (Lopez, O.J., Osorio, F.A. 2004).  PRRSV 
is eventually cleared from the body around 150 days post infection (pi), with the help of 
neutralizing antibodies (NAs) to the neutralizing epitope (NE) of GP5 (Lopez, O.J., 
Osorio, F.A. 2004, Mateu, E., Diaz, I. 2008). 
 There are currently several types of vaccines commercially available for PRRSV; 
none of which confer heterologous protection, safety, or the ability to distinguish 
vaccinated pigs from infected pigs (Kimman, T.G., Cornelissen, L.A., et al. 2009).  
Attenuated vaccines have been shown to revert to virulence, spread from vaccinated to 
non-vaccinated individuals, produce infection, and recombine with field isolates 
(Murtaugh, M.P., Genzow, M. 2011, Nielsen, H.S., Oleksiewicz, M.B., et al. 2001).  
Killed vaccines have been considered ineffective or of limited efficiency (Kimman, T.G., 
Cornelissen, L.A., et al. 2009, Murtaugh, M.P., Genzow, M. 2011).  Due to economic 
losses associated with PRRSV, there is a dire need for a safe, effective vaccine to 
PRRSV.  Virus-like particle (VLP) vaccines have been shown to be safe, effective, and 
offer the ability to differentiate non-vaccinated from vaccinated individuals for several 
viruses, including Ebola virus, canine parvovirus (CPV), porcine circovirus type 2 
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(CPV2) and bluetongue virus (BTV) (Noad, R., Roy, P. 2003, Crisci, E., Barcena, J., et al 
2012, Ye, L., Lin, Y., et al. 2006). 
 In this study, we show how PRRSV VLPs, derived from PRRSV M, N, GP5, and 
E proteins by using the recombinant baculovirus expression system in insect cells, are 
expressed and produced.  
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MATERIALS AND METHODS 
 
CELLS AND VIRUSES 
 CV-1 (simian) in Origin carrying the SV40 genetic material cells (Cos-1) derived 
from monkey kidney tissue and show high efficiency transfection, were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies Grand Island, NY), 
and maintained at 37°C in a 5% CO2 atmosphere.  Experiments performed with Cos-1 
cells were in a 6-well plate with a concentration of 4x10
5
 cells/ well.  Sf9 insect cells, 
derived from Spodoptera frugiperda, were cultured in HyClone
TM
 TNM-FH Insect Cell 
Culture Media (GE Healthcare Life Sciences, Logan, Utah) with 1X penicillin.  TriEx 
Sf9 cells, serum-free adapted Sf9 derived cells, were cultured in filtered Novagen 
TriEx
TM
 Insect Cell Media (Novagen, San Diego, CA).  Sf9 cells are adherent cells and 
are used only in the transfection of recombinant baculovirus, while the TriEx Sf9 cells 
are free floating cells that yield high levels of protein expression.  Incomplete media, 
used for recombinant baculovirus transfection of Sf9 cells, was filtered Grace’s Insect 
Media (Sigma, St. Louis, MO).  Sf9 cells and the initial TriEx Sf9 cell culture were 
maintained in a T-75 flask at 28°C in a foil covered Tupperware box.  Once 80-90% 
confluent, TriEx Sf9 cells were transferred to a shake culture and were maintained at 
150rpm and 28°C.  Sf9 cell concentration for T-75 flasks was 4x10
6
 cells/ flask and 
2x10
5
 cells/ well for 24-well plates.  TriEx Sf9 shaker cultured cells maintained a cell 
concentration between 2x10
5
 and 5x10
5
 cells/ ml in 50 mL, and 2x10
6 
cells/ mL in 20 mL 
for amplification of recombinant baculovirus.  cDNA was produced from previously 
extracted RNA of PRRSV-23983.   
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POLYMERASE CHAIN REACTION (PCR) 
 Previously extracted PRRSV-23983 RNA was reverse transcribed using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) and the 
cDNA produced was then subjected to first round PCR for amplification of PRRSV GP5, 
GP4, and E genes using the New England Biolabs Taq PCR kit (New England BioLabs 
Inc., Ipswich, MA).  Primers used for GP5 were forward primer (FP): 5’-GAT GAT CTC 
GAG GCC ACC ATG TTG GAG AAA TGC TTG ACC-3’ and reverse primer (RP): 5’- 
CGT ATG GGT AAG GAC GAC CCC ATT GTT CCG C-3’ (IDT Ref #’s FP: 
79600681; RP: 79600682), primers used for E were FP: 5’- GAT GAT CTC GAG GCC 
ACC ATG GGG TCC ATG CAA AGC CTT-3’ and RP: 5’- CGT ATG GGT ATA AGA 
TCT TCT GTA ATT GCT C-3’ (IDT Ref #’s FP: 7900683; RP: 79600684), and primers 
used for GP4 were FP: 5’- GAT GAT CTC GAG GCC ACC ATG GCT TCG TCC CTT 
CTT TTC-3’ and RP: 5’- CGT ATG GGT AAA TTG CCA ACA GAA TGG C-3’ (IDT 
Ref #’s FP: 52083932; RP: 52083933), which were synthesized by Integrated DNA 
Technologies (IDT, Coralville, IA).  The GeneAmp PCR system 2400 thermocycler 
(Applied Biosystems, Carlsbad, CA) was used to complete 35 cycles of step 2 PCR 
according to the programming below: 
 Step 1: Hold 94°C for 5 minutes 
 Step 2: 94°C for 30 seconds, 50°C for 30 seconds, 72°C for 30 seconds 
 Step 3: Hold 72°C for 10 minutes 
 Step 4: Hold 4°C for ∞ 
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After the PCR reaction was completed, loading dye was mixed with each PCR 
product, then was loaded and separated in an ethidium bromide-stained 1% agarose gel 
(w/v) and visualized by the UV Transilluminator (UVP, Upland, CA).  Concentration of 
PCR product was determined through NanoDrop ND-1000 Spectrophotometer. 
HA Stop tag, which will be used to identify proteins in future experiments, was 
incorporated into the first round PCR product via second round PCR using the respective 
first round PCR product as a template with the HA Stop RP (5’-ACT ACT GAA TTC 
GAT ATC GCG GCC GCT TAC GCG TAG TCC GGG ACG TCG TAT GGG TA-3’ 
(IDT Ref # 52385787)) and respective FP.  PCR was completed for GP4 and E proteins 
for 35 cycles of step 2 using the following programming: 
 Step 1: Hold 94°C for 5 minutes 
 Step 2: 94°C for 30 seconds, 47°C for 30 seconds, 72°C for 30 seconds 
 Step 3: Hold 72°C for 10 minutes 
 Step 4: Hold 4°C for ∞ 
PCR was completed for GP5 protein for 35 cycles of step 2 using the following 
programing:   
Step 1: Hold 94°C for 5 minutes 
 Step 2: 94°C for 30 seconds, 40°C for 30 seconds, 72°C for 30 seconds 
 Step 3: Hold 72°C for 10 minutes 
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 Step 4: Hold 4°C for ∞ 
Concentrations of PCR product were determined through the NanoDrop ND-1000 
Spectrophotometer. 
RESTRICTION ENZYME DOUBLE DIGESTION, GEL EXTRACTION, AND 
LIGATION WITH pCAGEN PLASMID 
PCR products, as well as pCAGEN plasmid (acquired from Dr. Li’s Lab) were 
subject to restriction enzyme double digestion with Xho1, Not1, and Cutsmart Buffer 
(New England BioLabs, Ipswich, MA) in a 37° water bath for 3 hours and 1 hour, 
respectively.  pCAGEN plasmid is used to contain our genes of interest after restriction 
enzyme double digestion and ligation, and will be replicated in competent cells.  The 
replication will include both pCAGEN as well as our genes of interest.  After restriction 
enzyme double digestion was complete, loading dye was mixed with each sample, then 
was loaded and separated in an ethidium bromide-stained 1% agarose gel (w/v) and 
visualized by the UV Transilluminator (UVP, Upland, CA) and cut from the gel. PCR 
products or pCAGEN was then extracted from the gel via the QIAquick Gel Extraction 
Kit (QIAGEN Sciences, Maryland).  Each PCR product was then mixed with pCAGEN, 
T4 DNA Ligase, and T4 DNA Ligase buffer (10X) (New England BioLabs, Ipswich, 
MA) in a 15°C water bath for ligation of plasmid with gene of interest.   
 Each ligation reaction was added to competent cells (Escherichia coli DH-5α) 
(New England BioLabs, Ipswich, MA), incubated on ice for 30 minutes, heat shocked for 
45 seconds in a 42°C waterbath, placed back on ice for 5 minutes, and incubated on the 
rocker for 1 hour at 37°C and 250rpm after adding Lennox L broth (LB) (Research 
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Products International Corp Mount Prospect, IL) for transformation.  The mixture was 
plated on LB plates with Ampicilin and allowed to incubate overnight at 37°C.  An 
isolated colony was selected from each LB plate, added to LB medium plus ampicillin, 
and incubated overnight on the rocker at 37°C and 250rpm.  pCAGEN-GP4, pCAGEN-
GP5, and pCAGEN-E was then extracted from respective competent cells following the 
Wizard Plus SV Minipreps DNA Purification System Protocol (Promega, Madison, WI).  
Restriction enzyme double digestion and gel electrophoresis were again performed to be 
certain the colony selected contained the insertion.  We discontinued our work with GP4 
at this point because this was the second unsuccessful experiment with GP4 and we 
needed to move forward with the project. 
 Restriction enzyme double digestion was performed on pCAGEN-GP5 and 
pCAGEN-E, as well as transfer plasmid pOET1 (Oxford Expression Technologies, 
Oxford, UK) with NOT1, XHO1, and Cutsmart Buffer in 37°C waterbath for 1 hour.  Gel 
extraction, ligation, transformation and screening of plasmid, and plasmid DNA 
extraction were performed on pOET1-GP5 and pOET1-E following protocols previously 
stated.  pOET1 transfer plasmid was used due to its ability to express high levels of 
foreign genes and its compatibility with recombinant baculovirus expression systems, 
which we will be using in further experiments. 
TRANSFECTION OF COS-1 CELLS 
 Extracted pCAGEN-GP5, pCAGEN-GP4, and pCAGEN-E was calculated at 4 μg 
DNA/ 6-well plate and added to raw DMEM media each in separate tubes, while 
Lipofectamine 3000 (Invitrogen, Carlsband, CA) was added to raw media in separate 
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tubes, and allowed to incubate at room temperature for 5 minutes.  Each DNA tube was 
combined with each Lipofectamine 3000 tube and allowed to incubate at room 
temperature for 20 minutes, up to 6 hours.  Each DNA/ Lipofectamine 3000 mixture was 
added to Cos-1 cells in separate wells of a 6-well plate, and allowed to incubate at 37°C 
with 5%CO2 for 4-6 hours.  Media was then removed and complete DMEM media was 
added to each well and allowed to incubate for 48 hours. 
WESTERN BLOT 
Harvested supernatant from pCAGEN-GP5, pCAGEN-GP4, and pCAGEN-E 
transfection of Cos-1 cells were added to TSE Buffer containing 10mM TrisHCl, 1M 
EDTA, 100mM NaCl with 20% sucrose, and ultracentrifuged for 1.5 hours at 45000rpm 
and 4°C.  pCAGEN-GP5, pCAGEN-GP4, and pCAGEN-E transfected Cos-1 cells were 
harvested and lysed with a lysis buffer containing 0.01M Tris-HCl, 0.14M NaCl, 0.025% 
NaN3, 1% Triton X-100, and with a protease inhibitor for 2 hours in 4°C and vortexed 
every 20 minutes.  Proteins where then separated in a SDS-PAGE gel (Novex by Life 
Technologies, Carlsband, CA) and transferred to a nitrocellulose membrane (Life 
Technologies, Gaithersburg, MD). The membrane was then blocked for 1h by rocking 
slowly at room temperature with 5% (w/v) milk powder in PBS plus 0.05% Tween 20 
(PBST). Next, primary antibody, monoclonal mouse anti-HA antibody (Sigma-Aldrich, 
St. Louis, MO) diluted 1:5,000 in blocking buffer (5% (w/v) milk powder in PBST) was 
added to the membrane and incubated overnight at 4°C on the rocker.  In a dark room, the 
secondary antibody, goat anti-mouse IRDye (LI-COR, Lincoln, NE) diluted 1:10,000 in 
PBST was added to the membrane and incubated for 1 hour rotating at room temperature.  
Bands were visualized using the ODESSY Infrared Imaging System (LI-COR, Lincoln, 
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NE).   
 The same procedure was performed on harvested supernatant and cells from 
TriEx Sf9 cells co-infected with recombinant baculovirus containing PRRSV proteins M, 
N, E, and GP5. 
TRANSFECTION OF SF9 CELLS 
 Sf9 cells were incubated in a 24-well plate for 1 hour at room temperature for the 
transfection of recombinant baculovirus.  The transfection mixture of flashBAC (Oxford 
Expression Technologies, Oxford, UK), Baculofectin (Oxford Expression Technologies, 
Oxford, UK), raw media, and LacZ (Oxford Expression Technologies, Oxford, UK) 
pOET1-E, or pOET1-GP5 at 500ng/ well was prepared and incubated for 15 minutes at 
room temperature.  With pOET1-E or pOET1-GP5 and flashBAC, a homologous 
recombination occurs which restores the function of a gene in the flashBAC DNA that is 
essential for replication of the recombinant baculovirus simultaneously inserting the gene 
of interest for the overexpression of that gene. Next, each transfection mixture was added 
to the center of its respective well of Sf9 cells and incubated for 5 hours at 28°C when 
complete media was then added.  After complete media was added, the transfection was 
allowed to incubate for 5 days at 28°C.  Supernatants were harvested and stored at 4°C.  
The supernatants contained the generated recombinant baculoviruses that encompassed 
PRRSV GP5 or E genes. 
IMMUNOFLUORESCENCE ASSAY (IFA) OF GP5 AND E INFECTED SF9 CELLS 
Formaldehyde in PBS (1:10) was added to pOET1-GP5 and pOET1-E infected 
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Sf9 cells for 10 minutes, followed by 0.2% Triton X-100 for 10 minutes.  Next a blocking 
buffer (10% fetal bovine serum (FBS) in PBS 1X) was added for 1 hour.  Primary 
antibody, mouse anti-HA at a 1:5,000 dilution in blocking buffer, was added and allowed 
to incubate at room temperature for 1.5 hours.  The mouse anti-HA is a monoclonal 
antibody for the HA stop tag that was added during second round PCR.  Secondary 
antibody, 5μL goat anti-mouse Alexa-546 (Life Sciences Advanced Technologies, St. 
Petersburg, FL) diluted in 1mL PBS, was incubated for 1 hour in the dark at room 
temperature.  Fluorescing cells were visualized with Olympus 1X70 Inverted Microscope 
(Olympus, Center Valley, PA). 
AMPLIFICATION AND TITRATION USING qRT-PCR OF RECOMBINANT 
BACULOVIRUS CONTAINING PRRSV GP5 AND E GENES 
Using a suspension culture of TriEx Sf9 cells passed 3 hours prior containing 4 x 
10
7
 cells/ 20 mL, 0.5mL recombinant baculovirus containing PRRSV GP5 or E from the 
collected supernatant after Sf9 transfection in previous experiments was added to each 
respective flask and incubated for 5 days on the shaker at 28°C and 150rpm.  
Recombinant baculovirus was harvested at day 5 by pouring cells into 50mL centrifuge 
tube and spun down at 2000rpm for 10 minutes.  The supernatant was collected and 
filtered through a 0.45μm syringe filter.  The same procedure was repeated to continue to 
amplify the recombinant baculovirus until desired amount of recombinant baculovirus is 
obtained. 
Virus titration was performed using the baculoQUANT ALL-IN-ONE
TM
 
Baculovirus DNA Extraction and Quantification Kit (Oxford Expression Technologies, 
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Oxford, UK).  To begin virus titration, a 10 fold serial dilution of virus internal standard 
was prepared by adding 10μL of the virus internal standard (10
8
 pfu/ mL) to 90μL of 
RNase free water and diluted to 10
3
 pfu/ mL, making a total of 6 internal standard 
dilutions.  80μL of each recombinant baculovirus stock, as well as the 6 internal standard 
dilutions, were centrifuged at 16,000x g/ 13,000rpm for 5 minutes in a microfuge.  The 
supernatant was removed and the virus pellet was resuspended in 20μL of lysis buffer by 
briefly vortexing.  All tubes were placed into the GeneAmp PCR system 2400 
thermocycler and ran according to the lysis program as follows: 
Step 1: 65°C for 15 minutes 
Step 2: 96°C for 2 minutes 
Step 3: 65°C for 4 minutes 
Step 4: 96°C for 1 minute 
Step 5: 65°C for 1 minute 
Step 6: 96°C for 30 seconds 
Step 7: 20°C hold 
Next, a master mix was prepared using reagents from the baculoQUANT ALL-
IN-ONE
TM
 Baculovirus DNA Extraction and Quantification Kit and Brilliant III Ultra-
Fast QPCR Master Mix (Agilent Technologies, Santa Clara, CA), and run in duplicate for 
each standard and sample.  Reference dye was diluted 50X (1μL reference dye in 49μL 
RNAse free water).  Master mix was prepared by adding 0.3μL diluted reference dye per 
sample, 3μL primer/ probe mix per sample, 10μL PCR mix (Brilliant II Ultra-Fast QPCR 
Master Mix) per sample, and 4.7μL water per sample.  18μL of master mix was added to 
each qRT-PCR tube, followed by viral DNA or diluted virus internal standard in their 
respective tubes.  Tubes were capped and centrifuged for 3 minutes at 12000rpm.   
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qRT-PCR was run on the ABI7900HT Real-Time Thermocycler (Applied 
Biosystems, Grand Island, NY) according to the following conditions: Reporter FAM, 
Quencher TAMRA, Stage 1: 95°C for 3 minutes, and Stage 2: 40 repeats of 95°C for 5 
seconds and 60°C for 15 seconds. 
CO-INFECTION OF TRIEX SF9 CELLS TO DETERMINE OPTIMAL 
MULTIPLICITY OF INFECTION (MOI) AND INCUBATION TIMES 
 TriEx SF9 cells were co-infected with recombinant baculoviruses containing 
PRRSV N, M, GP5, and E proteins at MOI of 2, 3, 5, or 10 with cell concentrations of 
1.5 x 10
7
 cells/ 10mL.  Recombinant baculoviruses containing PRRSV N and M were 
produced through previous experiments in our lab that has not been published.  Cells and 
supernatant were harvested at 24, 48, 72, and 96 hours by centrifuging at 2000rpm for 10 
minutes, and were subjected to western blot for protein expression analysis. 
CO-INFECTION OF TRIEX SF9 CELLS WITH OPTIMAL MOI AND INCUBATION 
TIMES FOR VLP PRODUCTION 
 TriEx SF9 cells were co-infected with recombinant baculoviruses containing 
PRRSV N, M, GP5, and E proteins at MOI of 2 for N, GP5, and E proteins, and MOI of 3 
for M protein with cell concentrations of 75 x 10
6
 cells/ 50mL.  Supernatants were 
harvested at 72 hours by centrifuging at 2000rpm for 10 minutes and filtering through a 
.45μm filter. 
TRANSMISSION ELECTRON MICROSCOPY (TEM) 
 Harvested supernatant from TriEx SF9 cells co-infected with recombinant 
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baculovirus containing PRRSV M, N, GP5, and E genes or uninfected TriEx cells were 
added to TSE Buffer containing 10mM TrisHCl, 1M EDTA, 100mM NaCl with 20% 
sucrose, and ultracentrifuged for 1.5 hours at 45000rpm and 4°C.  Supernatant was 
removed after untracentrifugation and the pellet was resuspended in 100μL 1X PBS.  
Samples were sent to Karen Bently, MS and the EM core facility of the University of 
Rochester Medical Center in Rochester, NY to be analyzed. 
RESULTS 
AMPLIFICATION AND ISOLATION OF PRRSV GP4, GP5, ANE E PROTEINS 
 For insertion of PRRSV GP4, GP5, and E proteins into the pCAGEN plasmid, 
amplification through PCR of genes of interest and isolation through gel extraction 
followed by restriction enzyme double digestion of PCR products was performed.  
Amplification and isolation of proteins were determined through gel electrophoresis.  
Bands were seen for GP4 at approximately 540bp, 600bp for GP5, and 200bp for E.  
Concentrations of PCR product after second round PCR were then determined to be 730 
ng/μL GP4, 530 ng/μL GP5, and 650 ng/μL E.  Concentrations of PCR product and 
pCAGEN after restriction enzyme double digestion and gel extractions were determined 
to be 4.9 ng/μL GP4, 7.2 ng/μL GP5, 6.9 ng/μL E. 
INSERTION AND SCREENING OF PRRSV GP4, GP5 AND E GENES INTO 
pCAGEN PLASMID 
 Genes were inserted into pCAGEN plasmid through ligation, followed by 
transformation of plasmids containing respective PRRSV genes into competent cells, 
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which were then plated on LB plus amp media and allowed to grow.  Colonies seen on 
plates had the complete pCAGEN plasmid that contained the cloned PRRSV GP4, GP5, 
or E genes.  The cut pCAGEN plasmid was used as the negative control and showed no 
growth.  The pCAGEN plasmid contains an ampicillin resistant gene when complete.  If 
it is cut, the plasmid will be susceptible to ampicillin. After allowing each of the 
transformed bacteria to grow in LB broth for 24 hours at 37° and 250rpm, plasmids were 
extracted and once again double digested for verification that the correct gene was 
inserted into the plasmid.  Bands were seen at approximately 540bp for GP4, 600bp for 
GP5, and 200bp for E after gel electrophoresis.  Concentrations of extracted plasmid 
were determined to be 252 ng/μL for GP4, 132 ng/μL for GP5, and 25.3 ng/μL for E. 
PRRSV GP5 AND E PROTEINS ARE EXPRESSED IN MAMMALIAN COS-1 
CELLS 
 Each purified plasmid DNA, pCAGEN-GP4, pCAGEN-GP5, and pCAGEN-E, 
was transfected into cos-1 mammalian cells at 4μg plasmid DNA per well of a 6 well 
plate, and allowed to incubate for 48 hours before harvesting the supernatant and cells.  
Protein expression of PRRSV GP4, GP5, and E proteins in mammalian cells was then 
verified through western blot (Figure 2.1).  We saw that both PRRSV GP5 and E were 
expressed in both cell lysate and supernatant of mammalian cells, with bands at 25kDa 
and 10kDa, respectively.  PRRSV GP4, 31kDa, was not seen in either cell lysate or 
supernatant, and therefore was eliminated from future studies.  Bands or slurs seen above 
protein bands can be explained by aggregates of structural proteins. 
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Figure 2.1: Western Blot analysis of PRRSV GP4, GP5, and E protein expression in 
transfected cos-1 cells.  After transfecting mammalian cos-1 cells with pCAGEN-GP4, 
pCAGEN-GP5, or pCAGEN-E for 48 hours, western blot analysis was performed on cell 
lysate and supernatant for protein expression.  Bands are seen for E protein (10 kDa) and 
GP5 (25 kDa) proteins in both the supernatant and cell lysate, but not for GP4.  
INSERTION AND SCREENING OF PRRSV GP5 AND E PROTEINS INTO pOET-1 
PLASMID 
Plasmids, pCAGEN-GP5, pCAGEN-E, and pOET-1, were subjected to restriction 
enzyme double digestion and gel extraction with the resulting concentrations of 11.3ng/ 
μL for GP5, 8.2ng/μL E, and 36.5ng/μL pOET-1.  PRRSV genes were inserted into 
pOET-1 plasmid through ligation, followed by transformation of plasmids containing 
respective PRRSV genes into competent cells, which were then plated and allowed to 
grow.  Colonies seen on plates contained successfully inserted PRRSV GP5 and E genes 
into the pOET-1 plasmid.  The cut pOET-1 plasmid was used as the negative control and 
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showed no growth, due to its susceptibility to ampicillin when not complete.  The 
complete plasmid will show resistance to ampicillin.  After allowing each of the 
transformed bacteria to grow in LB broth for 24 hours at 37° and 250rpm, plasmids were 
extracted and once again double digested for verification that the correct gene was 
inserted into the plasmid.  Bands were seen at approximately 600bp for GP5 and 200bp 
for E after gel electrophoresis.  Concentrations of extracted plasmid were determined to 
be 97.2 ng/μL for GP5, and 92.8 ng/μL for E. 
PRODUCTION OF PRRSV RECOMBINANT BACULOVIRUS GP5 AND E 
 SF9 cells were transfected using the flashBAC transfection mixture, pOET1-GP5, 
and pOET1-E for the production of recombinant baculoviruses containing PRRSV GP5 
and E.  According to Oxford Expression Technologies, the flashBAC system works by 
co-transfecting insect cells, SF9 cells, with the flashBAC virus DNA and pOET-1 
containing the gene of interest to produce recombinant baculoviruses.  The flashBAC 
DNA contains a gene that is partially deleted.  The homologous recombination of the 
flashBAC DNA with pOET-1 containing GP5 or E restores function of that partially 
deleted gene and thus allows for replication of the recombinant baculovirus in insect 
cells, while inserting the GP5 or E gene into the flashBAC DNA (Figure 2.2- retrieved 
from oetltd.com).  The produced recombinant baculovirus will replicate in the inset cells 
allowing for overexpression of GP5 and E.   
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Figure 2.2 FlashBAC Recombinant Baculovirus Expression System. (Retrieved from 
oetltd.com) The FlashBAC Recombinant Baculovirus Expression System creates a 
Recombinant Baculovirus that overexpresses our proteins of interest (GP5 and E).  It 
works by co-transfecting insect cells (SF9) with flashBAC with pOET1- GP5 or pOET1-
E. Homologous recombination of the virus with the insect cells restores function to the 
virus’ deleted gene, simultaneously inserting the gene of interest. The restored 
recombinant baculovirus genomes, and thus the inserted genes (GP5 and E), replicate to 
be harvested as the recombinant virus seed stock that is used to produce GP5 and E 
proteins.  
Transfection was proven to be effective by adding 2% x-gal to the control 
transfection well of LacZ and observing change in media color to blue.  An 
immunofluorescence assay (IFA) was also performed to confirm transfection of SF9 cells 
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with PRRSV recombinant baculovirus GP5 or E.  Results of the IFA are shown in Figure 
2.3.  PRRSV recombinant baculovirus GP5 and E were both observed under the 
fluorescent microscope and phase contrast microscope, while mock cells could only be 
visualized by the phase contrast microscope.  This shows that the transfection was 
effective for PRRSV GP5 and E. 
A    B    C 
        
Figure 2.3: IFA of transfected SF9 cells with PRRSV recombinant baculovirus GP5 
or E.  SF9 cells were incubated for 5 days after being transfected with PRRSV 
recombinant baculovirus GP5 or E, followed by an IFA.  Figure 2.2A shows PRRSV 
recombinant baculovirus GP5 is present in the transfected cells.  Figure 2.2B shows that 
PRRSV recombinant baculovirus E is also present in the transfected cells.  Figure 2.2C 
shows a negative control of mock cells with no staining.  This indicated that the 
transfection was effective.   
After infection of TriEx Sf9 cells with PRRSV recombinant baculovirus 
containing GP5 or E for amplification, viral titers were shown to be 6.94 x 10
8
 pfu/mL 
for GP5 and 6.19 x 10
8
 pfu/mL for E.   
CO-INFECTION OF TRIEX SF9 CELLS WITH PRRSV RECOMBINANT 
BACULOVIRUS N, M, GP5, AND E FOR PROTEIN EXPRESSION 
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To determine the optimal MOI and incubation time for protein expression co-
infection of TriEx SF9 cells with MOI of either 2, 5, or 10 of PRRSV recombinant 
baculoviruses N and M (from previous studies not published), and E at time points of 24, 
48, 72, and 96 hours was performed.  Results from the Western Blot show that MOI of 2 
at the 72-hour time point was the most ideal for protein expression for N and E, while M 
was only faintly visible at a MOI of 5 and time points of 72 and 96 hours (Figure 2.4).  
To further explore M and GP5, co-infection of M and GP5 in TriEx SF9 cells with MOI 
of 3 for M and MOI of 1 or 3 for GP5 was performed.  The results showed that the MOI 
of 3 worked for M, and MOI of either 1 or 3 worked for GP5 (Figure 2.5).  There are 
bands seen above and below bands for proteins that can be explained by aggregates of 
proteins or break down of proteins.  Structural proteins have been known to form 
heterodimers or homodimers.   For further experiments, MOI of 2 was used for GP5.   
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Figure 2.4: Protein Expression of PRRSV proteins M, N, and E post co-infection of 
TriEx SF9 cells.  TriEx SF9 cells were co-infected with M, N, and E at MOI of 2, 5, or 
10, and collected at 24, 48, 72, or 96 hours post infection for all samples.  The band for 
the M protein was only slightly visible at MOI of 5 at 72 and 96 hours post infection.  
The N protein was visible at all time points, as well as MOI, and showed the strongest 
band at 72 and 96 hours of 2 MOI.  The E protein was visible at all time points and MOI 
except for the 24 hour of 2 and 10 MOI.   
  
 
 
Figure 2.5: Protein Expression of PRRSV GP5 and M 72 hours post co-infection of 
TriEx cells.  Lanes 1 and 3 show bands for both GP5 and M with an MOI of 1 for GP5 
and 3 for M.  Lanes 2 and 4 show bands again for both GP5 and M with an MOI of 3 for 
both GP5 and M.   
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 TriEx SF9 cells (75 x 10
6
 cells/ 50 mL) were co-infected with recombinant 
baculovirus containing PRRSV M at an MOI of 3 and recombinant baculovirus 
containing PRRSV N, GP5, and E at an MOI of 2 for a large-scale production of VLPs.  
Western blot analysis was performed to confirm the expression of PRRSV proteins 
(Figure 2.6), and transmission electron microscopy (TEM) was performed to confirm the 
production of VLPs (Figure 2.7).  The negative control for TEM was TriEx Sf9 cells that 
had been grown at same conditions, but were not co-infected.  All desired proteins are 
expressed; GP5 is seen around 25 kDa, M at 18-19 kDa, N at 15 kDa, and E is seen 
around 10 kDa.  Again, bands can be seen above the protein bands, which could possibly 
be aggregates of heterodimers or homodimers of structural proteins.  VLPs that are 
similar in shape (spherical or oval) and size (approximately 50nm in diameter) were seen 
on TEM. 
 
 
 
 
 
 
Figure 2.6. Expression of four PRRSV proteins after co-infection.  Under optimal 
conditions, all four proteins of interest, PRRSV M, N, GP5, and E are expressed. 
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Figure 2.7 TEM of VLPs. VLPs were seen to be produced in a similar shape (spherical 
or oval) and size (approximately 50 nm in diameter) after co-infection of TriEx Sf9 cells 
with recombinant baculoviruses containing PRRSV structural proteins M, N, GP5, and E. 
 
DISCUSSION 
The use of virus-like particles (VLP) in vaccines and research has been well 
established in both humans and animal viruses (Noad, R., Roy, P. 2003).  VLPs are 
generated by the use of expression systems, including recombinant baculovirus 
expression in insect cells, bacteria, yeast, mammalian, or plant cells, that overexpress one 
or several structural proteins (non-infectious proteins) of the target virus, and 
spontaneously self-assemble into a structure similar to the desired virion (Noad, R., Roy, 
P. 2003, Crisci, E., Barcena, J., et al. 2012).  Bluetongue virus (BTV), canine parvovirus 
(CPV), Ebola virus, and porcine circovirus type 2 (PCV2) have utilized recombinant 
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baculovirus expression systems in the production of VLPs, and have significant potential 
for the use in vaccines, with Porcilis PCV® for PCV2 currently licensed and 
commercially available as a VLP-based vaccine (Harro, C.D., Pang, Y.S., et al. 2001 
Noad, R., Roy, P. 2003, Ye, L., Lin, J., et al. 2006, Crisci, E., Barcena, J., et al. 2012).  
The four major structural proteins of BTV, VP2, PV2, PV5, and VP9, are overexpressed 
using the recombinant baculovirus expression system for the formation of VLPs, while 
the VLPs produced for CPV are assembled from just one structural protein, VP2, in 
insect cells (Harro, C.D., Pang, Y.S., et al. 2001 Noad, R., Roy, P. 2003).  Being able to 
understand virus particle assembly is also an important aspect of VLPs, with an example 
of Norwalk virus that cannot be grown in cell culture (Roy, P., Noad, R. 2008).  Our 
previous unpublished studies have shown that the Membrane (M) and Nucleocapsid (N) 
proteins of PRRSV are able to assemble into VLPs when expressed both separately or in 
combination using the recombinant baculovirus expression system.  The exploration of 
other structural proteins of PRRSV, including Glycoprotein 4 (GP4), Envelope (E), and 
Glycoprotein 5 (GP5), which contains the major neutralizing epitope for PRRSV, for the 
production of VLPs has yet to be examined. The objectives of this study were to 
construct plasmids containing the GP4, GP5, and E genes of PRRSV that can be 
expressed in both mammalian and insect cells, to construct recombinant baculoviruses 
that express GP4, GP5, and E proteins of PRRSV for the purification of PRRSV VLPs, 
and produce VLPs similar in size and shape to PRRSV virions by expressing M, N, GP4, 
GP5, and E proteins simultaneously in insect cells. 
 We were able to isolate PRRSV GP4, GP5, and E genes through PCR by using 
constructed primers specific for each gene.  During second round PCR, the HA stop tag 
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was added to the C-terminus of each gene of interest for future identification of protein 
expression.  There are currently no monoclonal antibodies for these PRRSV specific 
proteins, so the HA stop tag was incorporated.  Once we confirmed isolation through gel 
electrophoresis, we inserted the genes of choice into the pCAGEN plasmid, which is 
ideal for transfection of mammalian cells.  The pCAGEN-GP4, pCAGEN-GP5, and 
pCAGEN-E were transfected into competent E. coli cells and insertion was confirmed by 
the presence of colony growth on LB plates with ampicillin.  Bacteria that grew 
contained the complete plasmid with the gene insertion making them resistant to 
ampicillin.  No growth on the plate containing the cut pCAGEN transfected cells was our 
negative control showing susceptibility to ampicillin.   
 PRRSV GP5 and E proteins were expressed in cos-1 mammalian cells, as shown 
in Figure 2.1. We first needed to show the expression of PRRSV proteins in mammalian 
cells due to PRRSV being a pig (mammal) virus and cos-1 cells have been shown to have 
a high efficiency for transfection.  We did not observe the expression of PRRSV GP4.  
This could be due to the possible interaction of the added HA stop tag at the C-terminal 
of GP4 (Du, Y., Pattnaik, A.K., et al., 2012).  The C-terminal of GP4 contains a 
hydrophobic domain that acts as the anchor of the GP4 protein to the ER membrane, 
where protein synthesis takes place (Du, Y., Pattnaik, A.K., et al., 2012). 
 For the production of VLPs, we choose the recombinant baculovirus expression 
system, which has been proven effective at over expressing multiple virus proteins, and 
was effective in previous studies with PRRSV M and N proteins (Stewart, M., Dovas, 
C.I., et al. 2012, Noad, R., Roy, P. 2003).  We showed the insertion of the genes of 
choice into the pOET1 plasmid by growth of colonies on LB plates with ampicillin.  They 
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showed resistance to ampicillin, while an unsuccessful transfection of cut pOET1 would 
have showed no growth or susceptibility to ampicillin.  The pOET1 plasmid was a 
suitable transfer vector for the flashBAC system. Recombinant baculoviruses containing 
PRRSV GP5 and E were both successfully produced and confirmed through IFA (Figure 
2.2).   
PRRSV N and E proteins showed the highest levels of expression at a MOI of 2 
and 72 hours post co-infection with recombinant baculoviruses N, E, and M (Figure 2.4).  
PRRSV M showed the highest level of expression at a MOI of 3 and 72 hours post co-
infection with recombinant baculovirus GP5 (Figure 2.5).  PRRSV GP5 showed the 
highest level of expression at MOI of 1-3 at 2 hours post co-infection with recombinant 
baculovirus M (Figure 2.5), and therefore we used an MOI of 2 throughout the 
experiments.  It is known that PRRSV N protein is the most abundant protein expressed 
in PRRSV infected cells, while M, E, and GP5 proteins have known interactions with 
other structural proteins, M and GP5 have been established to form heterodimers that are 
important for viral attachment (Spilman, M.S., Welbon, C., et 2009, Dokland, T. 2010, 
Gagnon, C.A., et al. 2000, Das, P.B., Dinh, P.X., et al. 2009). This information gives us 
the insight to why the N protein band is consistently stronger than the bands for M, GP5 
or E proteins during co-infection, as well as to the unknown bands seen in Figure 2.4 and 
2.5.  These results showed the optimal MOI and incubation period for expression of each 
of our proteins of interest to up-scale our VLP production.   
 Our experiments showed that all four PRRSV proteins of interest are expressed 72 
hours after co-infection with recombinant baculoviruses containing PRRSV N, M, GP5, 
and E (Figure 2.6).  The heterodimer formed between M and GP5 is important in viral 
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attachment and entry into host cells, while the E protein has been shown in the uncoating 
of PRRSV once internalized in host cells (Van Breedam, W., Van Gorp, H., et al 2010).  
N protein is the most immunogenic protein of PRRSV, and GP5 is important in the host’s 
production of neutralizing antibodies (Mateu, E., Diaz, I. 2008).  Based on this 
information and previous studies with PRRSV M and N proteins, a stable VLP similar in 
size and shape of PRRSV; PRRSV virion structure is spherical or oval in shape and 
approximately 50nm in diameter, should be produced by the overexpression of these four 
proteins and become an ideal vaccine candidate for PRRSV (Dokland, T. 2010).  We 
were able to confirm this with the help of Karen Bently, MS and the EM core facility of 
the University of Rochester Medical Center in Rochester, NY (Figure 2.7). 
 In conclusion, PRRSV GP5 and E are readily expressed in cos-1 mammalian cells 
while PRRSV GP4 was not.  PRRSV GP5 and E are also expressed in SF9 insect cells as 
part of recombinant baculovirus DNA through the flashBAC system.  Combined with 
previous experiments, PRRSV M, N, GP5, and E can be overexpressed in TriEx SF9 
insect cells when co-infected.  We can also conclude that VLPs are produced in a similar 
size and shape to the PRRSV virion by TEM.  Future studies include purification of 
produced VLPs to test the immunogenicity and protection efficacy of the PRRSV VLPs.  
More experiments are also needed to examine the nature of PRRSV GP4 and its 
expression in mammalian cells.  Studies to look at the production of VLPs with GP5 or E 
alone and different combinations of structural proteins would also be useful for 
understanding which combination of structural proteins produce the most VLPs similar in 
shape and size to the PRRSV virion.  
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CHAPTER 3: SUMMARY AND CONCLUSIONS 
Virus-like particles (VLPs) have been produced for several viruses, including 
Ebola virus, porcine circovirus type 2 (PCV2), bluetongue virus (BTV), and canine 
parvovirus (CPV), using the recombinant baculovirus expression system in insect cells 
(Stewart, M., Dovas, C.I., et al. 2012, Noad, R., Roy, P. 2003, Ye, L., Lin, J., et al. 2006, 
Crisci, E., Barcena, J., et al. 2012).  VLPs have been shown to be ideal candidates for 
vaccines due to their lack of viral DNA or RNA and similarities in viral capsid shape and 
size, resulting in a safe, effective, and differentiable immunogens (Crisci, E., Barcena, J., 
et al 2012).  Licensed and commercially available is the VLP-based vaccine Porcilis 
PCV® for PCV2, which is produced using the recombinant baculovirus expression 
system and has been proven safe, highly immunogenic, and effective against different 
PCV genotypes (Crisci, E., Barcena, J., et al. 2012).  Currently, the vaccines available for 
PRRSV have proven ineffective, unsafe, and costly (Kimman, T.G., Cornelissen, L.A., et 
al. 2009).  Previous studies our lab conducted showed PRRSV membrane (M) and 
nucleocapsid (N) proteins are able to produce VLPs alone or in combination with each 
other using the recombinant baculovirus expression system. 
In this study, we demonstrated that PRRSV Glycoprotein-5 (GP5), Envelope (E), 
M and N proteins are expressed in TriEx SF9 cells when co-infected with recombinant 
baculoviruses containing PRRSV GP5, E, M, and N genes.  We found the highest level of 
protein expression to be at 72 hours and 96 hours post co-infection, with a MOI of 2 for 
GP5, E, and N proteins, and a MOI of 3 for M protein. 
We were unable to incorporate the GP4 protein in our studies, which has known 
interactions with GP5 and aids in viral attachment leading to viral entry.  It seems that the 
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GP4 protein needs its intact C-terminal to anchor to the host’s ER membrane for protein 
synthesis (Du, Y., Pattnaik, A.K., et al. 2012).  The added HA stop tag, which is needed 
to identify desired proteins, may have been involved in the elimination of GP4 from our 
experiments.  At this time, there are not commercially available monoclonal antibodies to 
each of these proteins, so the HA stop tag is essential for identification.  Therefore further 
experiments that include moving the position of the added HA stop tag, as well as the 
removal of the HA stop tag, would be necessary to explore the reasoning for GP4 to not 
be expressed in our experiments with mammalian cells. 
Based on previous studies of PRRSV M and N proteins, we would expect to see 
VLPs produced from the co-infection of PRRSV recombinant baculovirus GP5, E, M, 
and N proteins that are similar in shape and size to PRRSV virions; figure 2.7 shows this.  
More experiments would be needed to determine if different combinations of PRRSV 
structural proteins or GP5 or E alone would be the optimal combination for VLP 
production.  With the immunogenic nature of the N and GP5 proteins, along with the 
interactions of E, GP5, and M and their attachment and entry properties, we would expect 
to produce highly immunogenic VLPs that would be safe for the use in a vaccine (Mateu, 
E., Diaz, I. 2008).   
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